PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 11440101-4 2001 which may interfere with the evaluation of platelet and vWF function by means of the PFA-100 in neonates. Foscarnet 85-88 von Willebrand factor Homo sapiens 56-59 11440101-8 2001 The results showed that short cord blood PFA-100 CTs were caused by a constituent of neonatal platelet-poor plasma, probably the neonatal high multimeric vWF. Foscarnet 41-44 von Willebrand factor Homo sapiens 154-157 11167770-1 2000 The PFA-100 measures platelet plug formation under shear stress and is strongly dependent on von Willebrand Factor (VWF) levels in plasma. Foscarnet 4-7 von Willebrand factor Homo sapiens 116-119 11167770-2 2000 We therefore hypothesized that elevated VWF levels, possibly as a result of acute inflammation, adversely influence PFA-100 results. Foscarnet 116-119 von Willebrand factor Homo sapiens 40-43 10928477-6 2000 This study demonstrated that the PFA-100 analyzer can accurately assess vWF-dependent platelet function and detect other platelet defects under high shear stress in complex patient populations. Foscarnet 33-36 von Willebrand factor Homo sapiens 72-75 10539883-0 1999 Use of a novel platelet function analyzer (PFA-100) with high sensitivity to disturbances in von Willebrand factor to screen for von Willebrand"s disease and other disorders. Foscarnet 43-46 von Willebrand factor Homo sapiens 93-114 10539883-13 1999 On the basis of these results, we conclude that the PFA-100 is highly sensitive to disturbances in VWF and to the presence of VWD and may thus provide a valuable screening test for VWD in certain specific circumstances (i.e., acute need conditions or remote testing sites; normal CT result generally effective as negative predictor, i.e. not severe VWD). Foscarnet 52-55 von Willebrand factor Homo sapiens 99-102 10525831-11 1999 These observations suggest that intraplatelet vWF, which is totally absent in type-III von Willebrand disease, plays an important function in the adhesion of platelets to the collagen-coated membrane of the PFA-100 system, simulating an injured vessel wall. Foscarnet 207-210 von Willebrand factor Homo sapiens 46-49 10468873-6 1999 In conclusion, the very high shear conditions in the PFA-100 make it very sensitive to the contribution of platelet VWF and to the ultralarge VWF multimers, indicating that the evaluation of the CT is a very simple and rapid tool to discriminate between good and non-responders to desmopressin. Foscarnet 53-56 von Willebrand factor Homo sapiens 116-119 10456451-11 1999 In general, changes in PFA-100 were paralleled by shortenings of the bleeding times and increases in plasma vWF levels. Foscarnet 23-26 von Willebrand factor Homo sapiens 108-111 10456451-12 1999 The PFA-100 test reflects vWF-dependent platelet function under high shear stress and could be useful in the diagnosis and therapeutic monitoring of patients with vWD. Foscarnet 4-7 von Willebrand factor Homo sapiens 26-29 10456451-12 1999 The PFA-100 test reflects vWF-dependent platelet function under high shear stress and could be useful in the diagnosis and therapeutic monitoring of patients with vWD. Foscarnet 4-7 von Willebrand factor Homo sapiens 163-166 16793722-0 1998 Ultrastructural analysis of the distribution of von Willebrand factor and fibrinogen in platelet aggregates formed in the PFA-100. Foscarnet 122-125 von Willebrand factor Homo sapiens 48-69 16793722-10 1998 Although fibrinogen was also present, its labeling was less intense suggesting that vWF is the major protein implicated in the platelet-platelet interactions in the aggregates formed in the PFA-100 system. Foscarnet 190-193 von Willebrand factor Homo sapiens 84-87 16793722-11 1998 This may be because of the high shear rate that occurs across the aperture which suggests that the PFA-100 is particularly sensitive for detecting abnormalities of vWF-platelet interactions. Foscarnet 99-102 von Willebrand factor Homo sapiens 164-167 25753785-4 2015 We have chosen to study the reliability of PFA-100 for screening VWF ristocetin cofactor (VWF:RCo) deficiency. Foscarnet 43-46 von Willebrand factor Homo sapiens 65-68 25753785-4 2015 We have chosen to study the reliability of PFA-100 for screening VWF ristocetin cofactor (VWF:RCo) deficiency. Foscarnet 43-46 von Willebrand factor Homo sapiens 90-93 25753785-7 2015 We have shown that the PFA-100 system, in our experience, constitutes an excellent screening test for detecting VWF:RCo deficiency, whatever the clinical situation, in "real-world" conditions. Foscarnet 23-26 von Willebrand factor Homo sapiens 112-115 25397410-11 2014 In thrombocytopenic (< 150/nL) patients with cirrhosis, normal PFA-100 results were associated with higher vWF-antigen levels (462.3 +- 235.9% vs. 338.7 +- 151.6%, P = 0.021). Foscarnet 66-69 von Willebrand factor Homo sapiens 110-113 24453831-0 2013 Von Willebrand factor antigen predicts response to double dose of aspirin and clopidogrel by PFA-100 in patients undergoing primary angioplasty for ST elevation myocardial infarction. Foscarnet 93-96 von Willebrand factor Homo sapiens 0-21 24453831-2 2013 Platelet Function Analyzer (PFA-100) with Collagen/Epinephrine (CEPI) is sensitive to functional alterations of VWF and also identifies patients with high on-treatment platelet reactivity (HPR). Foscarnet 28-31 von Willebrand factor Homo sapiens 112-115 24453831-12 2013 PFA-100 may be a useful tool to risk stratification in acute coronary syndromes given its sensitivity to VWF. Foscarnet 0-3 von Willebrand factor Homo sapiens 105-108 21352469-6 2011 RESULTS: VWF activation factor, indicating the proportion of circulating VWF able to bind to platelets, correlated negatively with peak transvalvular gradient and PFA-100 closure time. Foscarnet 163-166 von Willebrand factor Homo sapiens 9-12 21352469-6 2011 RESULTS: VWF activation factor, indicating the proportion of circulating VWF able to bind to platelets, correlated negatively with peak transvalvular gradient and PFA-100 closure time. Foscarnet 163-166 von Willebrand factor Homo sapiens 73-76 19538431-3 2009 The anti-von Willebrand factor (VWF) aptamer ARC1779 effectively inhibits VWF activity in plasma samples of TTP patients and thus shear-dependent platelet (PLT) function as measured by the PLT function analyzer PFA-100 (Dade Behring). Foscarnet 211-214 von Willebrand factor Homo sapiens 4-30 19538431-3 2009 The anti-von Willebrand factor (VWF) aptamer ARC1779 effectively inhibits VWF activity in plasma samples of TTP patients and thus shear-dependent platelet (PLT) function as measured by the PLT function analyzer PFA-100 (Dade Behring). Foscarnet 211-214 von Willebrand factor Homo sapiens 32-35 19584715-7 2009 This study confirms that there is a strong relationship between the presenting levels of plasma VWF and PFA-100 closure times, and that the supplementary combination of PFA-100 and VWF:CB testing might provide added clinical utility to current broadly applied testing strategies limited primarily to VWF:Ag, VWF ristocetin cofactor and factor VIII:coagulant. Foscarnet 104-107 von Willebrand factor Homo sapiens 96-99 18766263-0 2008 PFA-100 monitoring of von Willebrand factor (VWF) responses to desmopressin (DDAVP) and factor VIII/VWF concentrate substitution in von Willebrand disease type 1 and 2. Foscarnet 0-3 von Willebrand factor Homo sapiens 45-48 18766263-0 2008 PFA-100 monitoring of von Willebrand factor (VWF) responses to desmopressin (DDAVP) and factor VIII/VWF concentrate substitution in von Willebrand disease type 1 and 2. Foscarnet 0-3 von Willebrand factor Homo sapiens 100-103 18766263-1 2008 Dose-response relationship was studied between PFA-100 closure times (PFA CTs) and factor (F)VIII-von Willebrand factor (VWF) parameters in patients with von Willebrand disease (VWD) type 1 and type 2 before and after treatment with DDAVP (n=84) or FVIII/VWF concentrate (n=38). Foscarnet 47-50 von Willebrand factor Homo sapiens 121-124 18766263-5 2008 Of 12 patients with VWD type 2 treated with Haemate-P, six showed a correction of PFA CTs (<250 sec), which correlated with the normalisation of the VWF CB/Ag ratio. Foscarnet 82-85 von Willebrand factor Homo sapiens 152-155 18766263-9 2008 We conclude that PFA-100 might be an adequate instrument not only for diagnosis but also for monitoring of DDAVP responses and FVIII/VWF substitution of patients with VWD type 1 and 2, but this is dependent upon the type of VWD and the concentrate used. Foscarnet 17-20 von Willebrand factor Homo sapiens 133-136 18363340-10 2008 All three peptides inhibited GPIbalpha-vWF-mediated platelet aggregation induced under high shear conditions using the platelet function analyzer (PFA-100) with full blockade observed at 150 nM for OS-1. Foscarnet 147-150 von Willebrand factor Homo sapiens 39-42 16862528-5 2006 Ultimately, the high sensitivity of the PFA-100 to vWD and its simplicity of use provide its greatest strengths. Foscarnet 40-43 von Willebrand factor Homo sapiens 51-54 16862528-6 2006 However, because it is a global test system, and also sensitive to low hematocrit, low platelet counts, and platelet dysfunction (both congenital and acquired; e.g., secondary to medication such as aspirin) it must be recognized that the PFA-100 is neither specific for, nor predictive of, any particular disorder (inclusive of vWD). Foscarnet 238-241 von Willebrand factor Homo sapiens 328-331 14675411-10 2004 We demonstrate that in vitro aspirin-resistance, revealed by PFA-100 CT prolongation failure, is correlated to increased plasmatic vWF:RCo levels, reinforcing its particular importance in PFA-100 cartridges performance. Foscarnet 188-191 von Willebrand factor Homo sapiens 131-134